City cuts back on plan to regulate biolabs
Scientists feared loss of confidentiality
In the face of opposition from Harvard University, pharmaceutical giant Merck & Co., and the state biotechnology industry, Boston is scaling back its pioneering plan to regulate research on infectious organisms in laboratories within city limits. (Full article: 1172 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
